MedTrace Logo

TraStuzumAb-Radiotherapy : Impact on the Cerebral Prevention

NCT01613482 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2026-03-16

No results posted yet for this study

Summary

Evaluate the survival without metastasis in patients treated by Trastuzumab in association with other chemotherapies for a breast cancer expressing HER2-NEU.

Conditions

Interventions

RADIATION

cerebral prophylactic radiation

24Gy, 12 fractions of 2 Gy

DRUG

Trastuzumab

Weekly, 2mg/kg of corporal weight

DRUG

Other chemotherapy in association with Trastuzumab

other chemotherapy is possible to associate with Trastuzumab as well as a change of chemotherapy protocol is possible while maintening Trastuzumab 8 weeks is required between last injection of chemotherapy and first radiotherapy session

Sponsors & Collaborators

  • Centre Oscar Lambret

    lead OTHER

Principal Investigators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2009-08-31
Completion
2012-01-31

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01613482 on ClinicalTrials.gov